Pmv Pharmaceuticals, Inc.
A precision oncology company developing small-molecule drugs that fix a broken "guardian of the genome." The p53 protein normally stops cancer cells from growing, but mutations disable it in many tumors; PMV's therapies, including its lead candidate rezatapopt, aim to structurally correct these mutant proteins so they work again. Founded in 2013 by scientists including Arnold Levine, who discovered p53 in 1979, the company was originally incorporated as PJ Pharmaceuticals.
Bought 55.6K
Sold 1.50M
Bought 950.0K · Sold 474.5K
Sold 114.0K
Bought 950.0K
Sold 189.1K
Bought 950.0K
Bought 950.0K
Bought 55.6K
Granted 899.9K · Sold 100.4K
Sold 1.14M
Sold 17.5K
Sold 23.2K
Granted 132.5K · Sold 47.3K
Granted 82.2K · Sold 31.1K
Granted 76.2K · Sold 30.8K
Granted 28.6K · Sold 18.0K
Granted 3.9K · Sold 3.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Desai Keval +4 co-filers10% owner · 23 transactions | — | 11.07Mas of Jul 2021 | — | 55.6K | — |
| Orbimed Advisors LLC +1 co-filer10% owner · 2 transactions | — | 10.95M | — | — | 1.50M |
| Orbimed Advisors LLC +3 co-filers10% owner · 10 transactions | — | 6.59Mas of Mar 2022 | — | 950.0K | 474.5K |
| Orbimed Advisors LLC +2 co-filers10% owner · 2 transactions | — | 6.48Mas of Nov 2023 | — | — | 114.0K |
| Thompson Peter A.Director, 10% owner · 7 transactions | — | 5.58Mas of Sep 2020 | — | 950.0K | — |
| Chhabra Ashvin +8 co-filers10% owner · 30 transactions | — | 5.04Mas of Jun 2021 | — | — | 189.1K |
| Boxer Asset Management Inc. +4 co-filersFormer 10% Owner · 5 transactions | — | 3.84Mas of Sep 2020 | — | 950.0K | — |
| Bleyer Dalia +4 co-filersFormer 10% Owner · 2 transactions | — | 2.53Mas of Sep 2020 | — | — | — |
| Kolchinsky Peter +2 co-filers10% owner · 2 transactions | — | 1.71Mas of Sep 2020 | — | 950.0K | — |
| Oronsky Arnold LDirector, 10% owner · 5 transactions | — | 1.68Mas of Sep 2020 | — | 55.6K | — |
| Chhabra Ashvin +7 co-filersFormer 10% Owner · 4 transactions | — | 1.58Mas of Sep 2020 | — | — | — |
| Mack David HenryPresident and CEO, Director · 29 transactions | — | 1.27M | 899.9K | — | 100.4K |
| Schroeder ThiloDirector · 99 transactions | — | 1.10Mas of Oct 2021 | — | — | 1.14M |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Former 10% Owner · 1 transaction | — | 760.3Kas of Sep 2020 | — | — | — |
| Levine Arnold JDirector · 7 transactions | — | 409.8Kas of Sep 2021 | — | — | 17.5K |
| Ticktin RobertGeneral Counsel & COO · 1 transaction | — | 98.7Kas of Jul 2025 | — | — | 23.2K |
| Jalota DeepikaChief Development Officer · 7 transactions | — | 90.0Kas of Jul 2025 | 132.5K | — | 47.3K |
| Carulli MichaelChief Financial Officer · 3 transactions | — | 73.8K | 82.2K | — | 31.1K |
| Alland LeilaChief Medical Officer · 22 transactions | — | 45.9Kas of Sep 2023 | 76.2K | — | 30.8K |
| Kung WinstonCOO, CFO · 13 transactions | — | 10.6Kas of Nov 2022 | 28.6K | — | 18.0K |
| Heyman Richard A.Director · 12 transactions | — | 1.5Kas of Jun 2021 | 3.9K | — | 3.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +218.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.